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This review highlights a selection of recently published literature in the area of osteoarthritis biology.
Major themes transpiring from a PubMed search covering the year between the 2014 and the 2015
Osteoarthritis Research Society International (OARSI) World Congress are explored. Inﬂammation
emerged as a signiﬁcant theme, revealing complex pathways that drive dramatic changes in cartilage
homeostasis and in the synovium. Highlights include a homeostatic role for CXC chemokines in cartilage,
identiﬁcation of the zinc-ZIP8-MTF1 axis as an essential regulator of cartilage catabolism, and the dis-
covery that a small aggrecan fragment can have catabolic and pro-inﬂammatory effects through Toll-like
receptor 2. Synovitis can promote joint damage, partly through alarmins such as S100A8. Synovitis and
synovial expression of the pro-algesic neurotrophin, Nerve Growth Factor, are associated with pain.
Increasingly, researchers are considering speciﬁc pathogenic pathways that may operate in distinct
subsets of osteoarthritis associated with distinct risk factors, including obesity, age, and joint injury. In
obesity, the contribution of metabolic factors and diet is under intense investigation. The role of auto-
phagy and oxidative stress in age-related osteoarthritis has been further explored. This approach may
open avenues for targeted treatment of distinct phenotypes of osteoarthritis. Finally, a small selection of
novel analgesic targets in the periphery is brieﬂy discussed, including calcitonin gene-related peptide
and the neuronal sodium voltage-gated channels, Nav1.7 and Nav1.8.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Search criteria and selection process
Papers published online between February 2014 and April 2015
were identiﬁed by performing a PubMed search using the following
terms: “osteoarthritis”, “animal models”, “joint”, “cartilage”,
“chondrocytes”, “synovium”, “subchondral bone”, “risk factors”,
“ageing”, “obesity”, “post-traumatic”, and “pain”. From this search,
papers were selected in order to illustrate active research topics.
The papers included below are a personal selection and by no
means capture the wealth of meritorious studies published in the
past year. Rather, they were chosen because they exemplify some
overarching themes that are emerging in the ﬁeld, and it is hoped
that this selectionwill entice the reader to conduct a more in-depth
exploration of these themes. In addition, reference is made to
several recent review articles that provide background information
to these main themes.A.M. Malfait, Department of
University Medical Center,
t.com, anne-marie_malfait@
ternational. Published by Elsevier LMechanisms of inﬂammation in cartilage and synovium that
drive joint organ failure
All articular tissues e including cartilage, subchondral bone
(SCB), synovium, intra-articular fat, meniscus, ligaments, and peri-
articular muscles e can be affected by osteoarthritis (OA) pathol-
ogy. Individual tissues and the crosstalk between them likely
contribute to disease progression and pain (reviewed in Refs. 1,2).
Emphasis in the past year was on complex pathways, especially in
articular cartilage and synovium, that drive catabolism and low-
grade inﬂammation and how these processes affect global joint
metabolism (for review, see Ref. 3).Altered cartilage homeostasis
In the course of OA, articular chondrocytes are exposed to a
range of insults, including aberrant biomechanical stresses, pro-
inﬂammatory cytokines and chemokines and extensive changes
in the extracellular matrix (ECM). This provokes a phenotypic shift
in chondrocytes and disturbs cartilage homeostasis4. Several noveltd. All rights reserved.
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phenotypic changes were uncovered in the past year.mRNA decay in healthy vs OA chondrocytes
mRNA levels are not just controlled by the rate of synthesis but
also by the rate of degradation (i.e., “post-transcriptional regula-
tion”). Tew and colleagues examined mRNA decay in the tran-
scriptome of healthy and OA human chondrocytes, by microarray
analysis following an actinomycin D chase5. They reported that the
majority of chondrocyte-expressed transcripts were stable, but a
subset exhibited rapid decay with, interestingly, a clear bias toward
shortening of mRNA half-life in OA chondrocytes. Short-lived
transcripts included genes involved in transcriptional regulation,
localized to the nucleus, or involved in the regulation of pro-
grammed cell death. Additionally, the study identiﬁed genes
related to ECM turnover, such as ADAMTS-1, ADAMTS-5, ADAMTS-
9, the hyaluronic acid synthase, HAS2, the heparan sulfate sulfo-
transferase, HS3ST3A1, and also the NFkB complex component,
RELA. These short-lived transcripts were overall more highly
expressed in OA chondrocytes, which may mean that they are
associated with processes that rely on rapid and ﬂexible gene re-
sponses in OA5. This ﬁrst-of-its-kind study adds a new dimension to
the regulation of chondrocyte phenotypic stability.A homeostatic role for CXCR2 signaling in articular cartilage
CXC chemokines with an ELR motif are heparin-binding che-
mokines that signal through CXCR1 and CXCR2 and have been
targeted in inﬂammatory arthritis because of their chemotactic
properties. However, an unexpected homeostatic role for CXCR2
signaling in articular cartilage was revealed by Sherwood and co-
workers6, who found that the CXCR1/2 ligand, CXCL6, was present
in the territorial matrix of healthy human cartilage, bound to
heparan sulfate proteoglycans. In contrast, in early human or mu-
rine OA, CXCL6 was no longer detected. CXCR2-deﬁcient mice
showedmore severe cartilage damage 8 weeks after destabilization
of the medical meniscus (DMM) than wild types, while in vitro
disruption of CXCR2 signaling resulted in loss of mRNA for the
transcription factor, SOX9, COL2A1 mRNA and aggrecan mRNA in
primary human chondrocytes. The authors concluded that CXCL6
may support chondrocyte phenotypic stability through SOX9 and
that the loss of CXCL6 from degrading cartilage may contribute to
the characteristic changes in the phenotype of the OA chondrocyte.The zinc-ZIP8-MTF1 axis is an essential regulator of the catabolic
cascade in cartilage
Kim et al. reported that the zinc (Zn2þ) importer, ZIP8, was
increased in human and murine OA cartilage, raising intracellular
Zn2þ in chondrocytes7. ZIP8-mediated Zn2þ inﬂux upregulated
chondrocyte expression of catabolic enzymes, including MMP3,
MMP9, MMP12, MMP-13, and ADAMTS-5. Chondrocyte-speciﬁc
ZIP8 overexpression in mice (using a Col2a1 promoter) resulted in
cartilage damage and SCB sclerosis without overt synovitis. After
DMM surgery, these mice developed accelerated cartilage
destruction and SCB changes, while there was no effect on synovitis
and osteophytes. Conversely, chondrocyte-speciﬁc conditional Zip8
knock-out mice showed less cartilage damage and SCB sclerosis 8
weeks after DMM, without protection from synovitis and osteo-
phyte growth. Further, the transcription factor, MTF1, was identi-
ﬁed as an essential mediator of Zn2þ/ZIP8-induced catabolism. This
study establishes the zinc-ZIP8-MTF1 axis as a novel therapeutic
target in OA. It also substantiates the notion that cartilage damage
can drive changes in other joint tissues, in this case the SCB e but
remarkably, there was no effect on synovium or osteophytes.Catabolic and pro-inﬂammatory effects of an aggrecan fragment
mediated through TLR2
It has long been recognized that matrix molecules and frag-
ments thereof, including ﬁbronectin, tenascin C, and hyaluronan
fragments, can act as Damage Associated Molecular Patterns
(DAMPs). These DAMPs activate Pattern Recognition Receptors
(PRR) such as Toll-like receptors (TLR) and Receptor for Advanced
Glycation Endproducts (RAGE) that are locally expressed in the
joint, initiating a cascade of inﬂammatory cytokine production3.
Lees and co-workers investigated bio-activity of an aggrecan
fragment that is generated when ADAMTS-4/5 cleave the inter-
globular domain of the aggrecan core protein at the 374ARGS
cleavage site and the remaining G1-EGE373 stub is subsequently
cleaved by MMPs at DIPEN341, resulting in a 32-amino acid frag-
ment8. A synthetic 32-mer peptide caused a pro-catabolic, anti-
anabolic, and pro-inﬂammatory response in vitro in murine and
human chondrocytes, increasing mRNA expression for several
proteases, including MMP-13 and ADAMTS-5, and decreasing
mRNA for matrix molecules, including Col2A1 and aggrecan. These
effects are mediated through TLR2 and are NFkB-dependent. It was
conﬁrmed that the native, glycosylated 32-mer also has biological
activity. This is the ﬁrst demonstration that a TLR ligand can be
derived from one of the major cartilage macromolecules. This
aggrecan fragment adds to the pool of DAMPs that can originate
from degrading cartilage and amplify the pro-inﬂammatory and
catabolic network in the OA joint. The speciﬁc role of the 32-mer
aggrecan fragment within the innate immune network in vivo
needs to be determined.The pathogenic role of synovium
Clinical and imaging studies provide substantial evidence that
low-grade synovitis is associated with accelerated cartilage loss as
well as with symptoms (reviewed in Ref. 9). The recent studies
discussed below shed light on synovial pathways that may
contribute to OA disease.The role of the alarmins, S100A8 and S100A9, in OA with
pronounced synovitis
S100A8 and S100A9 are abundantly present in OA joints. A few
years ago, it was reported that these alarmins have pro-catabolic
effects on chondrocytes via TLR4, and that they contribute to OA
pathogenesis in collagenase-induced OA (CIOA), a model with
pronounced synovial inﬂammation, but not in the DMM model,
which exhibits low-grade synovitis10. The same authors now re-
ported that intra-articularly (IA) deposited adipose-derived stem
cells were efﬁcacious in reducing cartilage damage and osteophytes
in CIOA but not after DMM e indicating that synovial activation
drives the protective effects of locally administered adipose-
derived stem cells11. Efﬁcacy in CIOA was related to rapid sup-
pression of synovial activation, suppression of S100A8/A9 and IL-1
in the joint and of S100A8/A9 serum levels11. These ﬁndings further
reinforce the concept that these alarmins may contribute to OA
progression in subsets with a high degree of synovitis, and this
could be therapeutically exploited. OA joints may, of course, contain
a variety of DAMPs in addition to S100 proteins, including ECM
degradation products that signal through various PRRs. Hence, it is
of interest that female TLR1, TLR2, TLR4, TLR6, or MyD88 deﬁcient
mice were not protected from cartilage damage or synovial
inﬂammation 8 weeks after partial removal of the medial
meniscus12. These paradoxical ﬁndings further illustrate the need
for careful assessment of the role of the innate immune network in
different subsets of OA and at different stages of disease.
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after DMM and results in cartilage protection at 8 weeks
The pro-inﬂammatory G-Protein Coupled Receptor (GPCR),
proteinase-activated receptor-2 (PAR2), is elevated in human OA
cartilage and synovium. Jackson et al. compared the progression of
OA in wildtype vs PAR2/ mice up to 8 weeks after DMM and
demonstrated chondroprotection in PAR2/ mice, conﬁrming
older studies13. In vitro studies, however, failed to reveal a direct
chondroprotective effect of PAR2 ablation, suggesting that the
primary protective mechanisms of PAR2 ablation may occur
through extra-cartilaginous pathways. One week after DMM,
wildtype mice showed clear synovitis with increased synovial gene
expression of pro-inﬂammatory cytokines and metalloproteases
and increased numbers of CD4þ T-lymphocytes and activated
macrophages (assessed by FACS analysis), while PAR2-deﬁcient
mice contained fewer macrophages. This suggests that synovitis
early on after DMM surgery, although mild in comparison to more
inﬂammatorymodels, may be instrumental for disease progression.
Synovitis and pain
Stoppiello and co-workers aimed to identify histopathological
features associated with symptomatic knee OA14. They harvested
medial tibial plateaux and synovia from 29 asymptomatic donors
(postmortem) and 29 symptomatic donors (total knee replacement)
who were matched for macroscopic tibiofemoral chondropathy.
They analyzed similarities and differences in the histological fea-
tures between those two groups and found that the symptomatic
chondropathy group displayed greater loss of cartilage integrity
and alterations in chondrocyte morphology than did the asymp-
tomatic chondropathy group. However, the features most strongly
associated with painwere synovitis (8 out of 29 symptomatic knees
showed severe inﬂammation) and the synovial area that stained
positive for the pro-algesic neurotrophin, nerve growth factor
(NGF). NGF staining mostly co-localized with synovial ﬁbroblasts
but some CD68þ macrophages in the sublining of the synovium
also stained for NGF. These results underscore the relationship
between pain and synovitis and strongly suggest a pro-algesic role
for synovial NGF. Thus, deﬁning a role for NGF in synovitis may
provide a better rationale to pursue anti-NGF therapies in subsets
of patients.
Distinct risk factors drive distinct phenotypes of OA
Symptomatic OA is a highly heterogeneous disease, comprising
overlapping but distinct phenotypes that present with common
clinical and pathological features15. A clinically relevant stratiﬁca-
tion can be based on the risk factors that underlie the disease, such
as obesity, age, or joint injury. It is likely that these phenotypes may
warrant different therapeutic approaches, and researchers are
increasingly studying speciﬁc pathogenic pathways associated with
these risk factors.
Metabolic factors that link obesity and OA
Obesity is one of the strongest predictors of OA development16.
Weight increase alters joint loading and damages the joint, but
inﬂammatory and metabolic characteristics of obesity affect joint
health as well17. Unravelling the contributions of metabolic factors
to OA pathogenesis independently from weight increase is a
daunting task that requires innovative approaches.
Polyunsaturated fatty acids (PUFAs) and diet
Since diet is a modiﬁable factor that can be studied in a clinical
setting, it is of great potential interest to model its effect in animals.
McNeill et al. fed C57BL/NIA mice either a calorie-restricted (CR) oran ad libitum (AL) diet for 2 years. They found that Mankin score,
synovitis, and bone mineral density were similar between the
heavier ALmice and the lighter CRmice, and concluded that dietary
composition may matter more than caloric content for OA devel-
opment18. The authors went on to test this hypothesis by feeding
mice diets with different ratios of u-6 to u-3 PUFAs, since this ratio
is considered one of the most important dietary mediators of
inﬂammation19. Four diets were compared: (1) a high-fat diet
(HFD) rich in Saturated Fatty Acids (SFA); (2) an u-6 PUFA-HFD; (3)
an anti-inﬂammatory u-3 PUFA-HFD; and (4) a control diet. Weight
increasewas higher in all three HFD groups than in the controls, but
development of OA after DMM surgery was very different: while u-
3 PUFAs attenuated OA and synovitis in obese mice, SFA and u-6
PUFA independently acted as a detrimental factor. Interestingly, 12
weeks after DMM, u-6 mice had a higher synovial macrophage
score than the other groups. The study concluded that injury-
induced OA was associated with dietary content but not with
body weight. In contrast, Cai and co-workers reported that a life-
long reduction in the u-6:u-3 ratio did not alter the development
of idiopathic moderate knee OA in middle-aged mice20. They
studied development of spontaneous OA in Fat-1 transgenic mice,
which convert dietary u-6 to u-3 PUFAs endogenously. When fed
an u-6 PUFA diet for approximately a year, Fat-1 mice showed a
reduction in systemic TNF-a and IL-6, but they were not protected
from OA.
Collectively, these ﬁndings reinforce that distinct mechanisms
may drive distinct OA phenotypes e and this must be taken into
account when modeling the disease in small animals (reviewed in
Ref. 21).
Proteins related to lipid metabolism
Peroxisome proliferator-activated receptors (PPARs), PPARa,
PPARg, and PPARd, a family of nuclear receptors activated by lipid
ligands, are expressed in OA chondrocytes. PPARd functions in lipid
metabolism, apoptosis, and immune regulation. Ratneswaran and
co-workers reported that PPARd activation promotes fatty acid
oxidation in chondrocytes, as well as catabolic processes22.
Chondrocyte-speciﬁc PPARd knock-out mice were protected from
cartilage damage 8 weeks after DMM. This study was the ﬁrst to
interrogate the role of PPARd in OA and offers a glimpse into the link
between lipid metabolism and cartilage health.
Aging and OA
Aging is a key risk factor for OA16 and an active area of research
aims to resolve mechanisms that contribute to age-associated OA.
While all tissues in the joint changewith age, themajority of studies
aiming to solve the link between OA and aging focus on cartilage
aging and chondrocyte senescence (reviewed in Refs. 23,24).
The role of autophagy in cartilage homeostasis and aging
Autophagy is a cytoplasmic program for the removal of damaged
cellular components in conditions of oxidative stress25. Cellular
accumulation of damaged proteins and organelles, due to defective
autophagy, is one of the hallmarks of aging26. Carames and co-
workers reported the ﬁrst in vivo analysis of basal autophagy acti-
vation in cartilage, using GFP-LC3 reporter mice27. They found a
reduction in number of autophagic vesicles in chondrocytes with
age, and a decrease in the autophagy proteins, Atg5 and LC3.
Cartilage damage, monitored up to 28 months, progressed with age
and was subsequent to autophagy. This suggests that age-related
decreases in autophagy in chondrocytes contribute to joint dam-
age. The importance of autophagy for cartilage homeostasis was
also demonstrated in a study by Vasheghani et al., who subjected
cartilage-speciﬁc PPARg knock-out mice to DMM28. They found
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mediators, chondrocyte apoptosis, increased expression of
mammalian target for rapamycin (mTOR, a negative regulator of
autophagy) and suppression of autophagy markers. Importantly,
PPARg-mTOR double knock-out rescued this phenotype.
Since autophagy is a druggable pathway25, these ﬁndings sug-
gest that it could be targeted in age-associated OA. Indeed, an in vivo
study investigated the effect of IA administration of the mTOR in-
hibitor, rapamycin (twice a week for 8 weeks), on experimental OA
induced by DMM29. Treatment markedly attenuated cartilage
damage 8 and 12 weeks after surgery. This study was performed in
young mice, and it will be most interesting to see if the beneﬁcial
effect can be reproduced in models of age-associated OA.
Oxidative stress is major contributor to age-associated chronic
diseases, including OA
Mitochondrial dysfunction is one of the hallmarks of aging, and
impairment in the serine/threonine kinase AMPK, a master regu-
lator of cellular energy management, contributes to this26. AMPK
inhibits pro-catabolic responses of chondrocytes to biomechanical
stress and inﬂammation, and its signaling decreases with age3.
Zhao and collaborators reported that the chondroprotective effect
of AMPK is at least partly mediated by two major downstream
targets, peroxisome PPARg coactivator 1a (PGC-1) and FoxO3A30.
PGC-1 and FoxO3A expression levels decreased in cartilage from
aging mice and mice with OA. The role of FoxO transcription factors
in aging cartilage was further addressed in two studies by Akasaki
et al.31,32, who reported that in ageing human joints, expression of
FOXO1 and FOXO3 was reduced in the superﬁcial zone of cartilage
regions exposed to maximal weight bearing. They also found that
reduced expression of FoxO transcription in chondrocytes
increased susceptibility to cell death by oxidative stress.
Using human cartilage from donors 24e81 years, Loeser and
collaborators reported an age-related decline in proteoglycan syn-
thesis stimulated by insulin-growth factor (IGF)-1 and IGF-1 plus
osteogenic protein-1 (OP-1)33. Induction of oxidative stress
inhibited both IGF-1- and OP-1-stimulated proteoglycan synthesis.
Signaling studies showed that oxidative stress inhibited IGF-1-
stimulated Akt phosphorylation while increasing phosphorylation
of extracellular-regulated kinase (ERK), and that these effects were
greater in cells from older donors.
Post-traumatic OA (PTOA)
PTOA develops after joint injury and therefore offers the op-
portunity for early therapeutic intervention to prevent progressive
disease. Clinical and animal studies indicate that pro-inﬂammatory
cytokines are elevated after joint injury. Hence the role of local and
systemic inﬂammation in the development of PTOAwas tested in a
model where closed intra-articular fracture in the lateral tibial
plateau of the mouse knee results in OA34. Two treatment protocols
were compared: either a single IA injection of IL-1RA (anakinra) or
sTNFRII (etanercept) or systemic administration of IL-1RA or
sTNFRII for 4 weeks after fracture. Interestingly, only IA inhibition
of IL-1 signiﬁcantly prevented cartilage degeneration and synovial
inﬂammation. These data suggest that IL-1, rather than TNF-a, may
be critical in the acute phase following joint injury and that acute
treatment with local IL-1RA may be able to prevent cartilage
degeneration and synovitis in PTOA.
New targets for OA pain
Clinical OA is deﬁned by the presence of symptoms that drive
the sufferer to seek medical help. Pain is the major symptom of OA,
and current evidence supports the idea that it is generated throughcontinuous nociceptive peripheral input from the OA joint
(reviewed in Ref. 35). Therefore, researchers are exploring novel
analgesic targets in the joint and in the peripheral nervous system.
Nerve growth factor
Since initial clinical trial results with antibodies against NGF
were very encouraging, in spite of the occurrence of poorly un-
derstood side effects (reviewed in Ref. 36), several companies are
targeting NGF for OA pain (either through antibodies or through
blockade of its receptor, TrkA), thereby encouraging basic research
in this area. As discussed above, synoviocytes are a source of NGF
and synovial expression of this neurotrophin was found to be
associated with pain in human knee OA14. Cartilage, however, can
also be a source of NGF and two groups reported on stimuli that can
induce NGF in chondrocytes, supporting the concept that cartilage,
while aneural, may indirectly generate pain: IL-1b and visfatin
induced NGF in murine and human chondrocytes37 and TGF-b
induced NGFmRNA in bovine and human chondrocytes in an ALK5/
Smad2/3-dependent manner38. The latter study adds a new layer to
the complex pathogenic role of TGF-b in OA pathogenesis. A ﬁrst
study investigating the effect of NGF blockade in experimental OA
was reported39. A single dose of anti-NGF antibody exerted a long-
lasting beneﬁcial effect on pain during motion, as assessed by
monitoring gait, in the rat mono-iodoacetate (MIA) model, while
there was no effect on macroscopic joint lesions. Histology of the
joints was not performed in this study.
Novel targets under investigation in preclinical OA models
Several interesting studies explored putative novel targets for
OA pain in relevant models. One study uncovered a role for the
neuropeptide, calcitonin gene-related peptide (CGRP), in peripheral
neuronal sensitization (a hallmark of pain) in both the rat MIA and
the rat medial meniscal tear (MMT)model40. Researchers at Eli Lilly
tested the analgesic effect of a newly developed antibody against
CGRP in the same two models and found that CGRP blockade led to
a dose-dependent and prolonged pain reduction, as measured by
weight-bearing asymmetry41.
Experiments using in vivo electrophysiology to assess the effects
of selective antagonists of neuronal sodiumvoltage-gated channels,
Nav1.7- and Nav1.8, in the rat MIA model suggest that these
channels play a pivotal role in nociceptive pathways in this
model42. These channels merit further exploration as potential
targets for OA pain43.
Since the translational utility of different experimental OA
models for mimicking OA pain is currently poorly understood21, it
can be expected that more in-depth analysis of these novel targets
in different model systems will enhance our understanding of their
pathogenic role in OA-related pain.
Conclusion
Within the general concept that OA represents a failure of the
joint as an organ1, research in the past year has focused on a
multitude of pro-inﬂammatory and pro-catabolic pathways that
initiate andmaintain dramatic changes in chondrocyte phenotype,
cartilage homeostasis, and in the synovium (Fig. 1). The integration
of the different pathways results in complex networks that drive
disease progression, affect other articular tissues such as the SCB,
and promote pain. These networks may be modulated by factors
such as obesity, diet, age, and joint injury. This general picture
provides great complexity, but also offers a tremendous oppor-
tunity for targeted intervention in distinct but overlapping subsets
of OA.
Fig. 1. Research in the past year has focused on a multitude of pro-inﬂammatory and pro-catabolic pathways that initiate and maintain dramatic changes in chondrocyte phenotype,
cartilage homeostasis, and in the synovium. The integration of the different pathways results in complex networks that drive disease progression, affect other articular tissues such
as the subchondral bone, and promote pain. These networks may be modulated by factors such as obesity, diet, age, and joint injury.
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